

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Eastham et al.

Art Unit: 1621

Application No: 10/561,912

Examiner: S. A. Witherspoon

Confirmation No: 1376

Filed: March 23, 2007

Atty. Docket No: 31229-226445

For: PROCESS FOR THE  
HYDROFORMYLATION OF  
ETHYLENICALLY UNSATURATED  
COMPOUNDS

---

Customer No:

**26694**  
PATENT TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

A concise explanation of relevance of the items listed on form PTO/SB/08 is given for only non-English language listed items. Relevance of EP 1330309 (document BB) is given in the form of what is believed to be an English Language equivalent, US 20030191339 (document AC). Relevance of JP 08-134218 is given in the form of a machine translation provided by the Japanese Patent Office (document CD).

Office Actions from Assignee's pending applications that may contain relevant subject matter have been cited. Office Actions from issued patents (e.g. 7,371,705) that may contain relevant subject matter are not cited separately.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 31229-226445.

Dated: January 22, 2010

Respectfully submitted,  
By /Michael E. Nelson/  
Keith G. Haddaway, Ph.D.  
Registration No.: 46,180  
Michael E. Nelson, Ph.D.  
Registration No.: 64,115  
VENABLE LLP  
P.O. Box 34385  
Washington, DC 20043-9998  
(202) 344-4000  
(202) 344-8300 (Fax)  
Attorney/Agent For Applicant